BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
10 2월 2025 - 9:00PM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced
that the company will report its fourth quarter 2024 financial
results on Monday, February 24, 2025.
BioCryst management will host a conference call
and webcast at 8:30 a.m. ET that day to discuss the financial
results and provide a corporate update.
The live call may be accessed by dialing
1-844-481-2942 for domestic callers and 1-412-317-1866 for
international callers. A live webcast and replay of the call will
be available online in the investors section of the company website
at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a
deep commitment to improving the lives of people living with
complement-mediated and other rare diseases. BioCryst leverages its
expertise in structure-guided drug design to develop first-in-class
or best-in-class small-molecule and protein therapeutics to target
difficult-to-treat diseases. BioCryst has commercialized ORLADEYO®
(berotralstat), the first oral, once-daily plasma kallikrein
inhibitor, and is advancing a pipeline of small-molecule and
protein therapies. For more information, please visit
www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
BioCryst Pharmaceuticals (NASDAQ:BCRX)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
